AR077598A1 - Compuestos heterociclicos fusionados como modulares de canales ionicos - Google Patents
Compuestos heterociclicos fusionados como modulares de canales ionicosInfo
- Publication number
- AR077598A1 AR077598A1 ARP100102716A ARP100102716A AR077598A1 AR 077598 A1 AR077598 A1 AR 077598A1 AR P100102716 A ARP100102716 A AR P100102716A AR P100102716 A ARP100102716 A AR P100102716A AR 077598 A1 AR077598 A1 AR 077598A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- heteroaryl
- cycloalkyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Pyridine Compounds (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos que son inhibidores del canal de sodio y a su uso en el tratamiento de diversos estados patologicos, incluyendo enfermedades cardiovasculares y diabetes. Uso de los compuestos y a composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de la formula (1) en donde R1 es arilo o heteroarilo, en donde dicho arilo o heteroarilo están opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados, de modo independiente, del grupo que consiste en hidroxilo, halo, -NO2, CN, -SF5, -Si(CH3)3-O-CF3, -O-R20, -S-R20, -C(O)-R20, C(O)OH, -N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-S(=O)2-R26, -S(=O)2- R20, -S(=O)2-N(R20)(R22), alcoxi C1-3, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo, heteroarilo y heterociclilo; en donde dicho alcoxi, alquilo, alquenilo, alquinilo, heteroarilo, cicloalquilo o heterociclilo están opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados, de modo independiente, de hidroxilo, halo, -NO2, -O-CF3, -O-CF2, fenilo, heterociclilo, heteroarilo, cicloalquilo, -N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN y -O-R20, W1 es N o CR2 en donde R2 está seleccionado, de modo independiente, del grupo que consiste en hidrogeno, alquilo opcionalmente sustituido, amino, alcoxi opcionalmente sustituido, -CF3, -O-CF3, -CN y -N(R20)C(O)-R22; W2 es N o CR3 en donde R3 está seleccionado, de modo independiente, del grupo que consiste en hidrogeno, alquilo opcionalmente sustituido, -CF3, -halo y -O-R24; W3 es N o CR4, en donde R4 está seleccionado, de modo independiente, del grupo que consiste en hidrogeno, hidroxilo, halo, alquilo C1-4, alcoxi C1-3, -R25-N(R20)(R22), -R25-O-R20, -R25-C(O)-O-R20, -R25-C(O)-N(R20)(R22), -R25-C(O)-O-N(R20)(R22), -R25-N(R20)-C(O)-R22 y -R25-O-C(O)-N(R20)(R22), en donde dicho alquilo está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados, de modo independiente, de hidroxilo, halo, Q está seleccionado de un enlace covalente o alquinileno C2-4; X1 es N o CRa, en donde Ra es hidrogeno, alquilo C1-15, alcoxi C1-4, -C(O)-O-R26, -C(O)-N(R26)(R28), -N(R20)-S(=O)2-R20, cicloalquilo, arilo, heteroarilo, heterociclilo, en donde dicho alquilo está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados, de modo independiente, de hidroxilo, halo, -NO2, -O-CF3, -O-CHF2, cicloalquilo, -CN y alcoxi C1-4; y dicho alcoxi, cicloalquilo, arilo, heterociclilo o heteroarilo están opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados, de modo independiente, de hidroxilo, halo, -NO2, -O-CF3, -O-CHF2, fenilo, heterociclilo, heteroarilo, cicloalquilo, -N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN y -O-R20;o Ra es -Y-Z-R25-R23-R20, en donde, Y es un enlace covalente o está seleccionado de alquileno C1-3 opcionalmente sustituido con uno o dos grupos alquilo C1-3 o fluor; Z es alquinileno C2-4, -O-, -S-, -NRö, -NR5'-C(O)-, -NRö-C(O)-NR5'- o -C(O)-NR3-, en donde cada Rö y R5' es, de modo independiente, hidrogeno o alquilo inferior C1-6; y en donde también dicho alquilo está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados, de modo independiente, de hidroxilo, halo, -NO2, -O-CF3, -O-CF2, fenilo, heterociclilo, heteroarilo, cicloalquilo, -N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN y -O-R20, X2 es N o CRb; Rb está seleccionado del grupo que consiste en hidrogeno, alquilo sustituido, -CF3, -O-CF3, -O-R20, -S-R20, -N(R20)(R22), -N(R20)-C(O)-R22, -CF2-R20, -CF2-C(O)-O-R20 , -CF2-C(O)-N(R20)-S(=O)2-R26, -CF2-tetrazolilo, -C(O)-N(R20)-S(=O)2-R26, -N(R20)-C(O)-N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)( R22) y -N(R20)-S(=O)2-R26, -R25-heteroarilo opcionalmente sustituido, -R25-arilo opcionalmente sustituido; R20 y R22 están seleccionados en cada instancia, de modo independiente, del grupo que consiste en hidrogeno, alquilo C1-15, alquenilo C2-15, alquinilo C2-15, cicloalquilo, heterociclilo, arilo y heteroarilo, en donde el alquilo, alquenilo, alquinilo, heterociclilo, arilo y heteroarilo están opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados, de modo independiente, de hidroxilo, halo, alquilo, mono- o dialquilamino, alquilo o arilo o heteroarilamida, -NO2, -SO2R26, -CN, alcoxi C1-3, -CF3, -OCF3, arilo, cicloalquilo y heteroarilo; o cuando R20 y R22 están unidos a un átomo de nitrogeno comun R20 y R22 se pueden reunir para formar un anillo heterocíclico que entonces está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados, de modo independiente, de hidroxilo, halo, alquilo, mono- o dialquilamino, alquilo o arilo o heteroarilamida, -NO2, -SO2R26, -CN, alcoxi C1-3, -CF3 y -OCF3, arilo, cicloalquilo; R23 es un enlace covalente o está seleccionado del grupo que consiste en cicloalquileno, heterociclileno, arileno y heteroarileno, en donde el cicloalquileno, heterociclileno, arileno y heteroarileno están opcionalmente sustituidos con uno a tres sustituyentes seleccionados, de modo independiente, de hidroxilo, halo, alquilo, mono- o dialquilamino, alquilo o arilo o heteroarilamida, -NO2, -SO2R26, -CN, alcoxi C1-3, -CF3, -OCF3, arilo, cicloalquilo y heteroarilo; R24 está seleccionado en cada instancia, de modo independiente, de alquilo o arilo cualquiera de los cuales puede estar opcionalmente sustituido con 1, 2 o 3 grupos seleccionados, de modo independiente, de hidroxilo, -OCF3, halo, alcoxi C1-3, -O-R20 o alquil opcionalmente sustituido con halo, -NO2, -CF3, -O-CF3, -N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN o -O-R20; R25 es en cada instancia, de modo independiente, un enlace covalente o está seleccionado de alquileno C1-3 opcionalmente sustituido con uno o dos grupos alquilo C1-3; y R26 y R28 están seleccionados cada uno, de modo independiente, de hidrogeno, alquilo o cicloalquilo, en donde el alquilo, fenilo y cicloalquilo pueden estar sustituidos también con 1 a 3 sustituyentes seleccionados, de modo independiente, de hidroxilo, halo, alcoxi C1-4, -CF3 y -OCF3; o una de sus sales, ésteres, profármacos o solvatos farmacéuticamente aceptables, siempre que a) cuando X1 es CRa, Ra es -Y-Z-R25-R23-R20, Y no es un enlace covalente y Z es -O-, -S-, -SO2-, -C(O)-NR3-, -NR5'-C(O)- o NRö-, entonces R25 no pueda ser un enlace; b) cuando X1 es CRa, Ra es -Y-Z-R25-R23-R20,Y es enlace covalente y Z es -O-, -S-, -SO2- o NRö-, entonces R25 sea un enlace covalente y R23 no sea cicloalquileno; c) cuando Z es -NR5'-C(O)-, entonces Y no sea un enlace covalente; d) R23 y R25 no puedan ser enlaces covalentes; e) cuando X1 es CRa, Q es un enlace, R1 es heteroarilo y W1, W2 y W3 son todos CH, entonces el heteroarilo R1 pueda luego no estar sustituido con fenilo; f) cuando W1, W2 y W3 no son N, R2 es alquilo sustituido, X1 es CRa y X2 es N, entonces Ra no sea alquilo, cicloalquilo o heterociclilo; y g) cuando Q es un enlace covalente, R1 es fenilo, W1, W2 y W3 son CH, X1 es CRa y X2 es N, entonces Ra no sea alquilo C1-3 no sustituido; h) cuando Q es un enlace covalente, W1 y W2 son CH, W3 es NH, X1 es CRa y X2 es N, entonces R1 no sea heterarilo sustituido con arilo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22886409P | 2009-07-27 | 2009-07-27 | |
US36003710P | 2010-06-30 | 2010-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR077598A1 true AR077598A1 (es) | 2011-09-07 |
Family
ID=42751632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102716A AR077598A1 (es) | 2009-07-27 | 2010-07-27 | Compuestos heterociclicos fusionados como modulares de canales ionicos |
Country Status (22)
Country | Link |
---|---|
US (2) | US8952034B2 (es) |
EP (1) | EP2464645B1 (es) |
CN (1) | CN102725290B (es) |
AR (1) | AR077598A1 (es) |
AU (1) | AU2010276537B2 (es) |
CA (1) | CA2774715C (es) |
CY (1) | CY1119584T1 (es) |
DK (1) | DK2464645T3 (es) |
EA (1) | EA025824B1 (es) |
ES (1) | ES2642586T3 (es) |
HR (1) | HRP20171454T8 (es) |
HU (1) | HUE034911T2 (es) |
LT (1) | LT2464645T (es) |
ME (1) | ME02847B (es) |
NZ (1) | NZ598942A (es) |
PL (1) | PL2464645T3 (es) |
PT (1) | PT2464645T (es) |
RS (1) | RS56410B1 (es) |
SI (1) | SI2464645T1 (es) |
TW (2) | TWI490217B (es) |
UY (1) | UY32805A (es) |
WO (1) | WO2011014462A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933236B2 (en) | 2012-05-22 | 2015-01-13 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
CN102725290B (zh) | 2009-07-27 | 2016-03-09 | 吉利德科学股份有限公司 | 作为离子通道调节剂的稠合杂环化合物 |
PT2588197E (pt) | 2010-07-02 | 2015-02-09 | Gilead Sciences Inc | Compostos heterocíclicos fundidos como moduladores do canal de iões |
WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
CN105693645B (zh) | 2011-05-10 | 2018-10-09 | 吉利德科学公司 | 作为离子通道调节剂的稠合杂环化合物 |
TWI478908B (zh) * | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
US20140221286A1 (en) * | 2011-09-21 | 2014-08-07 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
BR112014006924B1 (pt) | 2011-09-27 | 2020-10-06 | Genfit | Derivados de triazolopiridazinas 6-substituídas como agonistas de rev-erb |
RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
MX2014005304A (es) | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
WO2013112932A1 (en) | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
CA2898679A1 (en) * | 2013-03-14 | 2014-09-25 | Xenon Pharmaceuticals Inc. | Substituted triazolopyridines and methods of use thereof |
EP2970156B1 (en) | 2013-03-15 | 2018-07-25 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
JO3367B1 (ar) * | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
EP3074377B1 (en) | 2013-11-27 | 2018-10-17 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
GB201321742D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321745D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
CN105829303B (zh) * | 2013-12-20 | 2018-11-06 | 吉利德科学公司 | 作为离子通道调节剂的稠合杂环化合物 |
ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
KR102502485B1 (ko) | 2014-01-21 | 2023-02-21 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
TW201613908A (en) * | 2014-02-13 | 2016-04-16 | Gilead Sciences Inc | Solid forms of an ion channel modulator |
JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック, インコーポレイテッド | 治療用化合物及びその使用方法 |
NZ737536A (en) | 2015-05-22 | 2019-04-26 | Genentech Inc | Substituted benzamides and methods of use thereof |
GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
KR20180067561A (ko) | 2015-09-28 | 2018-06-20 | 제넨테크, 인크. | 치료 화합물 및 그의 사용 방법 |
CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
CN109071426A (zh) | 2016-03-30 | 2018-12-21 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
MA46546A (fr) | 2016-10-17 | 2021-05-05 | Genentech Inc | Composés thérapeutiques et leurs procédés d'utilisation |
WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
CA3045121A1 (en) * | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11028075B2 (en) | 2018-02-26 | 2021-06-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
JP2021519788A (ja) | 2018-03-30 | 2021-08-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物 |
US11866439B2 (en) * | 2018-05-30 | 2024-01-09 | Praxis Precision Medicines, Inc. | Ion channel modulators |
EA202092908A1 (ru) * | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
CA3162893A1 (en) * | 2019-11-26 | 2021-06-03 | Praxis Precision Medicines, Inc. | Ion channel modulators |
WO2021126923A1 (en) * | 2019-12-19 | 2021-06-24 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Cd206 modulators their use and methods for preparation |
WO2023211852A1 (en) * | 2022-04-26 | 2023-11-02 | Praxis Precision Medicines, Inc. | Treatment of neurological disorders |
Family Cites Families (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL128591C (es) * | 1965-07-02 | |||
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4230705A (en) * | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
US4244953A (en) * | 1979-10-24 | 1981-01-13 | American Cyanamid Company | Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines |
US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4812565A (en) * | 1982-09-30 | 1989-03-14 | A. H. Robins Company, Incorporated | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4654343A (en) * | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4746655A (en) * | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
DE4010488A1 (de) | 1990-03-31 | 1991-10-02 | Hoechst Ag | Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten |
CA2044564A1 (en) * | 1990-06-28 | 1991-12-29 | Quirico Branca | Amino acid derivatives |
CN1060467A (zh) | 1990-09-25 | 1992-04-22 | 武田药品工业株式会社 | 1,3-苯并嗪衍生物、其生产方法和用途 |
JPH04209692A (ja) | 1990-12-03 | 1992-07-31 | Asahi Glass Co Ltd | フォトクロミック材料 |
DE69209576D1 (de) | 1991-05-10 | 1996-05-09 | Takeda Chemical Industries Ltd | Pyridinderivate, deren Herstellung und Anwendung |
DE69232854T2 (de) | 1991-06-28 | 2003-09-04 | Smithkline Beecham Corp | Bizyklische fibrinogenantagonisten |
US5939412A (en) * | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
US5674863A (en) * | 1991-10-18 | 1997-10-07 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
JPH06107647A (ja) | 1992-08-12 | 1994-04-19 | Takeda Chem Ind Ltd | 1,3−ベンゾオキサジン誘導体の製造法 |
US6011150A (en) * | 1992-11-13 | 2000-01-04 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
US5442055A (en) | 1992-11-13 | 1995-08-15 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
GB9225860D0 (en) | 1992-12-11 | 1993-02-03 | Smithkline Beecham Plc | Novel treatment |
GB9226302D0 (en) | 1992-12-17 | 1993-02-10 | Smithkline Beecham Plc | Pharmaceuticals |
US5550229A (en) | 1993-06-23 | 1996-08-27 | Tanabe Seiyaku Co., Ltd. | Alkylation process for preparing azetidinone compound and starting compound therefor |
DE19526173A1 (de) | 1995-07-18 | 1997-01-30 | Hoechst Ag | Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung |
JPH09157262A (ja) | 1995-12-08 | 1997-06-17 | Tanabe Seiyaku Co Ltd | アゼチジノン誘導体及びその合成中間体の製法 |
GB9619492D0 (en) | 1996-09-18 | 1996-10-30 | Smithkline Beecham Plc | Novel treatment |
WO1998047885A1 (en) | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
JP3964053B2 (ja) | 1997-07-10 | 2007-08-22 | 三井化学株式会社 | 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法 |
CN1131887C (zh) | 1997-09-08 | 2003-12-24 | 尤尼利弗公司 | 促进酶活性的方法 |
CN1110498C (zh) * | 1998-01-21 | 2003-06-04 | 默克·夏普-道姆公司 | 作为gaba受体的配体的三唑并-哒嗪衍生物 |
US6455522B1 (en) | 1998-02-11 | 2002-09-24 | Bristol-Myers Squibb Pharma Company | Cyclic sulfonamide derivatives as metalloproteinase inhibitors |
CN1293665A (zh) | 1998-02-18 | 2001-05-02 | 神经研究公司 | 新化合物及其用作阳性ampa受体调节剂 |
US6479506B1 (en) * | 1998-06-16 | 2002-11-12 | Merck Sharp & Dohme Ltd. | Triazolo-pyridine derivatives as ligands for GABA receptors |
EP1123297A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
AU4145200A (en) | 1999-05-07 | 2000-11-21 | Takeda Chemical Industries Ltd. | Cyclic compounds and uses thereof |
MXPA02002126A (es) | 1999-08-27 | 2002-09-18 | Procter & Gamble | Metodos de lavanderia que conservan el color, que emplean componentes de formulacion zwitterionicos. |
MXPA02002123A (es) | 1999-08-27 | 2002-10-17 | Procter & Gamble | Metodos de lavanderia que conservan el color, que emplean componentes de formulacion cationicos. |
WO2001016275A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Fast-acting formulation components, compositions and laundry methods employing same |
EP1206516A1 (en) | 1999-08-27 | 2002-05-22 | The Procter & Gamble Company | Stability enhancing formulation components, compositions and laundry methods employing same |
EP1206519B1 (en) | 1999-08-27 | 2005-11-30 | The Procter & Gamble Company | Stable formulation components, compositions and laundry methods employing same |
WO2001016110A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Bleach boosting components, compositions and laundry methods |
TR200201062T2 (tr) | 1999-08-27 | 2003-02-21 | The Procter & Gamble Company | Formülasyon bileşenlerinin denetimli kullanılabilirliği ve bundan yararlanılan bileşimler. |
AU5652001A (en) | 2000-05-15 | 2001-11-26 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
RU2272030C2 (ru) | 2000-08-01 | 2006-03-20 | Оно Фармасьютикал Ко., Лтд. | Производные 3,4-дигидроизохинолина и фармацевтический агент, включающий его в качестве активного ингредиента |
US20020072518A1 (en) | 2000-08-29 | 2002-06-13 | Khanna Ish Kumar | Bicyclic alphavbeta3 antagonists |
JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
EP1354602B1 (en) | 2000-12-26 | 2006-10-04 | Sankyo Company, Limited | Medicinal compositions containing diuretic and insulin resistance-improving agent |
HUP0303415A2 (hu) | 2001-03-09 | 2004-01-28 | Pfizer Products Inc. | Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények |
US6998408B2 (en) * | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
JP2005089298A (ja) | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
JP2003277384A (ja) | 2002-03-26 | 2003-10-02 | Kyorin Pharmaceut Co Ltd | 縮合ニ環式ピリジン誘導体 |
JP2003321461A (ja) | 2002-04-25 | 2003-11-11 | Kyorin Pharmaceut Co Ltd | 縮合ビフェニル誘導体 |
MXPA05001785A (es) * | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de cromona como inhibidores de las metaloproteinasas de matriz. |
PA8579601A1 (es) * | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
US7005523B2 (en) * | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
AU2003262073A1 (en) | 2002-09-20 | 2004-04-08 | Tsumura And Co. | Antitussives |
US20040204404A1 (en) * | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
AU2003294235A1 (en) | 2002-10-22 | 2004-05-13 | The Trustees Of The University Of Pennsylvania | Fragments and activity of rel protein in m. tuberculosis adn other uses thereof |
ES2278213T3 (es) * | 2002-11-07 | 2007-08-01 | MERCK & CO., INC. | Derivados de fenilamina como inhibidores de la dipeptidilpeptidasa en el tratamiento o la prevencion de la diabetes. |
NZ540468A (en) | 2003-01-13 | 2008-03-28 | Univ California | Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator |
AR044503A1 (es) | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
DE10317526A1 (de) | 2003-04-16 | 2004-11-04 | Degussa Ag | Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen |
EP1622916A4 (en) | 2003-04-17 | 2008-11-05 | Merck & Co Inc | Heterocyclic CYCLOPENTYLTETRAHYDROISOCHINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY |
EP1631546A1 (en) * | 2003-04-25 | 2006-03-08 | H. Lundbeck A/S | Sustituted indoline and indole derivatives |
WO2005002520A2 (en) | 2003-07-01 | 2005-01-13 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
MXPA06001494A (es) * | 2003-08-05 | 2007-05-11 | Vertex Pharma | Compuestos de piramidina condensados como inhibidores de canales ionicos gatillados por tension. |
US20050239767A1 (en) * | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
AU2004305318A1 (en) | 2003-12-18 | 2005-07-07 | Pfizer Products Inc. | Methods of treating acute inflammation in animals with p38 MAP kinase inhibitors |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
GB0412986D0 (en) * | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
WO2006002470A1 (en) | 2004-06-30 | 2006-01-12 | Monash University | Chiral ligands for asymmetric catalysis |
JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
JP2007297283A (ja) | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
US7572783B2 (en) | 2004-08-13 | 2009-08-11 | Amgen Inc. | Substituted benzofused heterocycles |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
CN101005877A (zh) | 2004-08-23 | 2007-07-25 | 默克公司 | 作为用于治疗或预防糖尿病的二肽基肽酶-ⅳ抑制剂的稠合三唑衍生物 |
ATE518852T1 (de) | 2004-09-13 | 2011-08-15 | Merck Sharp & Dohme | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten |
WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
WO2006091897A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
JP5794721B2 (ja) | 2005-05-17 | 2015-10-14 | サーコード バイオサイエンス インコーポレイテッド | 眼障害の治療のための組成物および方法 |
TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US7495111B2 (en) | 2005-06-17 | 2009-02-24 | Wyeth | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7572808B2 (en) | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
WO2007004028A2 (en) | 2005-06-30 | 2007-01-11 | Ranbaxy Laboratories Limited | Processes for the preparation of penems and its intermediate |
GB0516963D0 (en) * | 2005-08-18 | 2005-09-28 | Carbonite Corp | Liquid dispensers |
EP1932549B1 (en) | 2005-08-26 | 2016-12-28 | AMNOS Co., Ltd. | Dried amnion and method for drying treatment of amnion |
WO2007038138A2 (en) * | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
EP1940850A2 (en) | 2005-09-23 | 2008-07-09 | Schering Corporation | Fused tetracyclic mglur1 antagonists as therapeutic agents |
WO2007047604A2 (en) | 2005-10-18 | 2007-04-26 | Elixir Pharmaceuticals, Inc. | Sirt1 inhibition |
TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
EP1954268B1 (en) | 2005-11-18 | 2012-09-26 | Merck Sharp & Dohme Corp. | Spirolactam bicyclic cgrp receptor antagonists |
AU2006316627A1 (en) | 2005-11-18 | 2007-05-31 | Merck Sharp & Dohme Corp. | Spirolactam aryl CGRP receptor antagonists |
TW200734342A (en) | 2005-12-15 | 2007-09-16 | Astrazeneca Ab | New compounds for the treatment of cardiac arrhythmias |
US20070142376A1 (en) * | 2005-12-16 | 2007-06-21 | Alcon, Inc. | Control of intraocular pressure using alk5 modulation agents |
US8013073B2 (en) | 2005-12-30 | 2011-09-06 | Chevron Oronite Company Llc | Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds |
JP2009531390A (ja) * | 2006-03-31 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
CA2654842A1 (en) | 2006-06-12 | 2007-12-21 | Vertex Pharmaceuticals Incorporated | Thienopyrimidines useful as modulators of ion channels |
EP2035372A1 (en) | 2006-06-29 | 2009-03-18 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
JP5642963B2 (ja) | 2006-06-30 | 2014-12-17 | スネシス ファーマシューティカルズ,インコーポレイティド | ピリジノニルpdk1阻害剤 |
WO2008007661A1 (fr) | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique tricycique et son utilisation |
AU2007272009A1 (en) * | 2006-07-12 | 2008-01-17 | Syngenta Limited | Triazolopyridine derivatives as herbicides |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
CA2665214A1 (en) * | 2006-10-06 | 2008-05-29 | Abbott Laboratories | Novel imidazothiazoles and imidazoxazoles |
WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
WO2008051547A1 (en) * | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
US8399452B2 (en) | 2006-10-28 | 2013-03-19 | Methylgene Inc. | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors |
US20100099676A1 (en) * | 2006-11-02 | 2010-04-22 | Shionogi & Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
US20080153840A1 (en) | 2006-12-21 | 2008-06-26 | Luiz Belardinelli | Reduction of cardiovascular symptoms |
US8076350B2 (en) | 2006-12-22 | 2011-12-13 | Abbott Laboratories | Spirocyclic azaadamantane derivatives and methods of use |
WO2008094909A2 (en) | 2007-01-29 | 2008-08-07 | Xenon Pharmaceuticals Inc. | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
WO2008106077A1 (en) * | 2007-02-28 | 2008-09-04 | Merck & Co., Inc. | Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers |
WO2008108445A1 (ja) | 2007-03-07 | 2008-09-12 | Takeda Pharmaceutical Company Limited | ベンゾオキサゼピン誘導体およびその用途 |
GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
WO2008144483A2 (en) | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
WO2009026444A1 (en) | 2007-08-22 | 2009-02-26 | President And Fellows Of Harvard College | Ryanodine channel binders and uses thereof |
KR20100054856A (ko) * | 2007-09-12 | 2010-05-25 | 와이어쓰 엘엘씨 | 히스타민-3 길항제로서의 이소퀴놀리닐 및 이소인돌리닐 유도체 |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
KR20100101666A (ko) | 2007-12-19 | 2010-09-17 | 제넨테크, 인크. | 8-아닐리노이미다조피리딘 및 항암제 및/또는 소염제로서의 이들의 용도 |
EP2231669A1 (en) * | 2008-01-09 | 2010-09-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Phosphodiesterase inhibitors |
WO2009100380A1 (en) * | 2008-02-06 | 2009-08-13 | Cv Therapeutics, Inc. | Use of ranolazine for treating pain |
WO2009137499A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
DE102008024182A1 (de) | 2008-05-19 | 2009-11-26 | Merck Patent Gmbh | Verbindungen für organische elektronische Vorrichtung |
AU2009261764B2 (en) | 2008-06-17 | 2013-01-10 | Astrazeneca Ab | Pyridine compounds |
WO2010006292A1 (en) | 2008-07-11 | 2010-01-14 | Neumedics | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
WO2010018686A1 (ja) | 2008-08-12 | 2010-02-18 | 日本曹達株式会社 | 含窒素ヘテロ環誘導体および農園芸用殺菌剤 |
CA2734449A1 (en) | 2008-08-18 | 2010-02-25 | Ube Industries, Ltd. | Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto |
EP2337559A2 (en) | 2008-09-04 | 2011-06-29 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
US20100113461A1 (en) * | 2008-10-29 | 2010-05-06 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds |
US8389500B2 (en) * | 2008-10-30 | 2013-03-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
US9040508B2 (en) | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
WO2010077686A1 (en) | 2008-12-08 | 2010-07-08 | Sirtris Pharmaceuticals, Inc. | Isoindolinone and related analogs as sirtuin modulators |
FR2943342B1 (fr) * | 2009-03-20 | 2011-03-04 | Servier Lab | Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
BRPI1012282A2 (pt) | 2009-03-27 | 2015-09-22 | Presidio Pharmaceuticals Inc | inibidores de anel fundidos da hepatite c. |
US20100305093A1 (en) | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
CN102725290B (zh) | 2009-07-27 | 2016-03-09 | 吉利德科学股份有限公司 | 作为离子通道调节剂的稠合杂环化合物 |
NZ597833A (en) | 2009-09-28 | 2014-01-31 | Hoffmann La Roche | Benzoxazepin pi3k inhibitor compounds and methods of use |
CN102791687B (zh) | 2009-12-18 | 2015-02-11 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
PT2588197E (pt) * | 2010-07-02 | 2015-02-09 | Gilead Sciences Inc | Compostos heterocíclicos fundidos como moduladores do canal de iões |
WO2012019076A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
WO2012019071A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
EP2643316A2 (en) | 2010-11-24 | 2013-10-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture |
CN105693645B (zh) * | 2011-05-10 | 2018-10-09 | 吉利德科学公司 | 作为离子通道调节剂的稠合杂环化合物 |
TWI478908B (zh) * | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (es) * | 2011-07-01 | 2018-04-28 | ||
WO2013112932A1 (en) | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
-
2010
- 2010-07-26 CN CN201080043104.0A patent/CN102725290B/zh active Active
- 2010-07-26 ES ES10737724.4T patent/ES2642586T3/es active Active
- 2010-07-26 EA EA201290121A patent/EA025824B1/ru unknown
- 2010-07-26 SI SI201031540T patent/SI2464645T1/sl unknown
- 2010-07-26 WO PCT/US2010/043264 patent/WO2011014462A1/en active Application Filing
- 2010-07-26 NZ NZ598942A patent/NZ598942A/en active Application Filing
- 2010-07-26 ME MEP-2017-235A patent/ME02847B/me unknown
- 2010-07-26 DK DK10737724.4T patent/DK2464645T3/en active
- 2010-07-26 HU HUE10737724A patent/HUE034911T2/hu unknown
- 2010-07-26 AU AU2010276537A patent/AU2010276537B2/en active Active
- 2010-07-26 PT PT107377244T patent/PT2464645T/pt unknown
- 2010-07-26 RS RS20170990A patent/RS56410B1/sr unknown
- 2010-07-26 PL PL10737724T patent/PL2464645T3/pl unknown
- 2010-07-26 EP EP10737724.4A patent/EP2464645B1/en active Active
- 2010-07-26 LT LTEP10737724.4T patent/LT2464645T/lt unknown
- 2010-07-26 US US12/843,702 patent/US8952034B2/en active Active
- 2010-07-26 CA CA2774715A patent/CA2774715C/en active Active
- 2010-07-27 AR ARP100102716A patent/AR077598A1/es not_active Application Discontinuation
- 2010-07-27 TW TW099124710A patent/TWI490217B/zh active
- 2010-07-27 UY UY0001032805A patent/UY32805A/es not_active Application Discontinuation
- 2010-07-27 TW TW104112388A patent/TWI542587B/zh active
-
2014
- 2014-05-09 US US14/274,422 patent/US9371329B2/en active Active
-
2017
- 2017-09-28 HR HRP20171454TT patent/HRP20171454T8/hr unknown
- 2017-10-04 CY CY20171101028T patent/CY1119584T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1119584T1 (el) | 2018-03-07 |
ES2642586T3 (es) | 2017-11-16 |
LT2464645T (lt) | 2017-10-25 |
HRP20171454T8 (hr) | 2018-01-12 |
CN102725290B (zh) | 2016-03-09 |
HUE034911T2 (hu) | 2018-03-28 |
CN102725290A (zh) | 2012-10-10 |
PT2464645T (pt) | 2017-10-11 |
DK2464645T3 (en) | 2017-10-23 |
RS56410B1 (sr) | 2018-01-31 |
AU2010276537B2 (en) | 2015-04-16 |
TWI490217B (zh) | 2015-07-01 |
US20140303158A1 (en) | 2014-10-09 |
CA2774715C (en) | 2018-04-03 |
NZ598942A (en) | 2014-02-28 |
EA201290121A1 (ru) | 2012-10-30 |
US20110021521A1 (en) | 2011-01-27 |
EP2464645A1 (en) | 2012-06-20 |
EA025824B1 (ru) | 2017-02-28 |
US8952034B2 (en) | 2015-02-10 |
UY32805A (es) | 2011-02-28 |
TW201116528A (en) | 2011-05-16 |
CA2774715A1 (en) | 2011-02-03 |
AU2010276537A1 (en) | 2012-05-24 |
ME02847B (me) | 2018-01-20 |
PL2464645T3 (pl) | 2017-12-29 |
EP2464645B1 (en) | 2017-07-05 |
SI2464645T1 (sl) | 2017-10-30 |
TW201542545A (zh) | 2015-11-16 |
WO2011014462A1 (en) | 2011-02-03 |
US9371329B2 (en) | 2016-06-21 |
HRP20171454T1 (hr) | 2017-12-01 |
TWI542587B (zh) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR077598A1 (es) | Compuestos heterociclicos fusionados como modulares de canales ionicos | |
CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
PE20140961A1 (es) | Inhibidores macrociclicos de serina proteasas de hepatitis c | |
AR086319A1 (es) | Compuestos heterociclicos fusionados como moduladores de canal ionico | |
EA201170096A1 (ru) | Замещенные производные пиримидона | |
AR076264A1 (es) | Triazolopiridinas sustituidas y analogos de estas | |
AR060489A1 (es) | Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol | |
BR112014027143A2 (pt) | pirrolobenzodiazepinas | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
AR053149A1 (es) | Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis | |
AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
EA201170237A1 (ru) | Производные карбаматов алкилтиазолов, их получение и их применение в терапии | |
ECSP099216A (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR072301A1 (es) | Derivados de acido fenoxicroman carboxilico 6-sustituido utiles en el tratamiento y/o prevencion de enfermedades alergicas e inflamatorias, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos y compuestos intermediarios. | |
AR074916A1 (es) | Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparacion, composiciones farmaceuticas y su uso en enfermedades cardiovasculares. | |
AR101222A1 (es) | Derivados de piridona | |
AR069643A1 (es) | Derivados diazenidiolatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |